Neutral endopeptidase inhibition: the potential of a new therapeutic approach in cardiovascular disease evolves.
Veelken
Roland
R
Schmieder
Roland E
RE
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000201:enzymology; D003925:Diabetic Angiopathies / Q000201:enzymology / Q000517:prevention & control; D019332:Endothelin-1 / Q000502:physiology; D000072396:Endothelin-Converting Enzymes; D006801:Humans; D008666:Metalloendopeptidases; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D051381:Rats
D000806:Angiotensin-Converting Enzyme Inhibitors; D019332:Endothelin-1; D011480:Protease Inhibitors; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D015260:Neprilysin; D000072396:Endothelin-Converting Enzymes